Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Top Cited Papers
- 4 November 2010
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 363 (19), 1812-1821
- https://doi.org/10.1056/nejmoa1002965
Abstract
Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody–drug conjugate brentuximab vedotin (SGN-35).This publication has 29 references indexed in Scilit:
- Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphomaBritish Journal of Haematology, 2008
- Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22British Journal of Haematology, 2008
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphomaCancer, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s LymphomaTransplantation and Cellular Therapy, 2006
- Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin’s DiseaseOncology Research and Treatment, 2005
- Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody DisulfidesBioconjugate Chemistry, 2005
- Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic FactorCancer Research, 2005
- High Expression of the CC Chemokine TARC in Reed-Sternberg Cells: A Possible Explanation for the Characteristic T-Cell Infiltrate in Hodgkin's LymphomaThe American Journal of Pathology, 1999
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992